Vivek Subbiah: Key publications leading to Nobel Prize 2024, published in 1993

Vivek Subbiah shared a post on LinkedIn:

“BREAKING NEWS : Just in!

– The 2024 Nobel Prize in Physiology or Medicine has been awarded to Drs. Victor Ambros & Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.

– This year’s hashtag Nobel Prize in Physiology or Medicine honours two scientists for their discovery of a fundamental principle governing how gene activity is regulated. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation.”

He also added:

“Key publications leading to Nobel Prize 2024 were published in 1993.

CELL X 2 and NATURE X 1

– Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854. doi:10.1016/0092-8674(93)90529-y

– Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855-862. doi:10.1016/0092-8674(93)90530-4

– Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kurodak MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinvasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86-89. doi:10.1038/35040556″

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.